Palisade Bio Updates on Strategic Collaboration with Strand Life Sciences

Palisade Bio updates on advancement of its strategic collaboration with Strand Life Sciences

Overview

Palisade Bio, Inc., a biopharmaceutical company, provided an update on key areas of progress for its previously announced strategic collaboration with Strand Life Sciences (Strand), a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

Under Present Collaboration

Under the collaboration through an extensive analysis of transcriptomics datasets and clinical biomarkers, Palisade Bio and Strand have identified promising PDE4-related biomarkers associated with UC pathology, providing valuable insights for targeted therapeutic interventions.

Key areas of progress include:

• Candidate predictive biomarker identification: Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified, paving the way for the development of innovative precision medicine approaches for treatment of UC patients with PDE4-inhibitors.
• Patient stratification: Ongoing research focuses on refining patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC.
• Pipeline development: Progress has been made in refining Palisade’s precision medicine approach, integrating clinical biomarkers, disease activity measures, and transcriptomics data, to tailor personalized UC therapies.

Words from CMO: Palisade Bio

Dr. Mitch Jones, CMO at Palisade Bio stated, “We remain committed to advancing precision medicine solutions for UC and other inflammatory indications. Collaborative efforts with Strand and other partners will continue to drive innovation and transform the landscape of UC treatment.”

Words from CEO: Palisade Bio

“Looking ahead, as we pioneer innovative precision medicine approaches, Palisade aims to become a leader in developing precision medicine solutions within inflammatory and fibrotic indications, creating value for investors and helping patients,” added JD Finley, Palisade Bio’s CEO.

Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!